An interventional study of Extracorporeal Shockwave Therapy in Patellar Tendinopathy, sponsored by Ahmed Alshimy. Active, not recruiting at 1 site in Egypt. Open to participants aged 15 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-09-01.
Sponsored by Ahmed Alshimy · Not applicable, Interventional, and Treatment
Patellar tendinopathy (PT) is a commonly used term for the clinical manifestation of patellar tendon pain and functional limitation with multifactorial etiology. It occurs in both athletes and general population in all age groups. It is often characterized as an overuse injury resulting from chronic failure of the healing response that is not strictly linked to inflammatory or degenerative processes.
Once enrolled, participants were examined by a physiotherapist, and received the first application of ESWT (week 0). At weekly intervals, they received three more applications and on the day of the last application (week 3), a control clinical examination was performed. In the 12th-week follow-up after the last application week 15), a final examination including joint position sense, balance and kinesiophobia evaluation was performed.
Exclusion Criteria:
Device: Extracorporeal Shockwave Therapy
The low-energy focused ESWT was applied using the BTL-6000 FSWT device with piezoelectric generator and a coupling pad which modulates penetration depth to 0-35 mm. The setting was chosen based on ISMST guidelines (https://shockwavether apy.org). Energy flux density varied between 0.14 and 0.18 mJ/ mm2 due to patient tolerance, frequency was set at 8 Hz. A total of 2000 shocks were applied semi-statically to the most defined pathological area in the patellar tendon followed by2000 shocks dynamically to the quadriceps muscle.
Digital inclinometer
Time frame: 4 months
Tampa scale for Kinesiophobia
Time frame: 4 months
Biodex balance system (overall stability index)
Time frame: 4 months
Biodex balance system (Anteroposterior)
Time frame: 4 months
Biodex balance system (Mediolateral)
Time frame: 4 months
Plan to share: No
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ahmed Alshimy